ATE500845T1 - Anthracyclin-anti-cd74-antikörperkonjugate - Google Patents
Anthracyclin-anti-cd74-antikörperkonjugateInfo
- Publication number
- ATE500845T1 ATE500845T1 AT04703628T AT04703628T ATE500845T1 AT E500845 T1 ATE500845 T1 AT E500845T1 AT 04703628 T AT04703628 T AT 04703628T AT 04703628 T AT04703628 T AT 04703628T AT E500845 T1 ATE500845 T1 AT E500845T1
- Authority
- AT
- Austria
- Prior art keywords
- anthracycline
- conjugates
- chemotherapeutic drug
- targeting antibody
- antibodies conjugates
- Prior art date
Links
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 229940044683 chemotherapy drug Drugs 0.000 abstract 2
- 230000008685 targeting Effects 0.000 abstract 2
- 229940045799 anthracyclines and related substance Drugs 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44212503P | 2003-01-24 | 2003-01-24 | |
| PCT/US2004/001367 WO2004067038A1 (en) | 2003-01-24 | 2004-01-20 | Anthracycline-antibody conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE500845T1 true ATE500845T1 (de) | 2011-03-15 |
Family
ID=32825184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04703628T ATE500845T1 (de) | 2003-01-24 | 2004-01-20 | Anthracyclin-anti-cd74-antikörperkonjugate |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20040202666A1 (de) |
| EP (1) | EP1594548B1 (de) |
| JP (2) | JP4805137B2 (de) |
| KR (1) | KR101053739B1 (de) |
| CN (1) | CN1764478B (de) |
| AT (1) | ATE500845T1 (de) |
| AU (2) | AU2004207494C1 (de) |
| BR (1) | BRPI0406574A (de) |
| CA (1) | CA2510664C (de) |
| DE (1) | DE602004031714D1 (de) |
| IL (1) | IL169769A (de) |
| MX (1) | MXPA05007851A (de) |
| PL (1) | PL378012A1 (de) |
| RU (1) | RU2349343C2 (de) |
| WO (1) | WO2004067038A1 (de) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7138262B1 (en) | 2000-08-18 | 2006-11-21 | Shire Human Genetic Therapies, Inc. | High mannose proteins and methods of making high mannose proteins |
| US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| AU2002311919B8 (en) | 2001-05-11 | 2007-03-22 | Ludwig Institute For Cancer Research Ltd | Specific binding proteins and uses thereof |
| US8877901B2 (en) | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
| US7591994B2 (en) | 2002-12-13 | 2009-09-22 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
| US8658773B2 (en) | 2011-05-02 | 2014-02-25 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
| US8148335B2 (en) * | 2004-06-23 | 2012-04-03 | Children's Hospital & Research Center Oakland | De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy |
| HRP20120994T1 (hr) | 2006-02-07 | 2012-12-31 | Shire Human Genetic Therapies, Inc. | Stabilizirana smjesa glukocerebrozidaze |
| US9090693B2 (en) | 2007-01-25 | 2015-07-28 | Dana-Farber Cancer Institute | Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease |
| CA2680854C (en) | 2007-03-15 | 2017-02-14 | Ludwig Institute For Cancer Research | Treatment method using egfr antibodies and src inhibitors and related formulations |
| WO2008120101A2 (en) | 2007-04-02 | 2008-10-09 | Philogen S.P.A. | The ed-a antigen of fibrinogen is associated with the neovasculature of tumour metastases |
| LT2631248T (lt) | 2007-06-15 | 2018-04-25 | Medigene Ag | Navikų gydymas, naudojant specifinį anti-l1 antikūną |
| US10202442B2 (en) | 2007-07-25 | 2019-02-12 | Philogen S.P.A. | Antigen associated with lung cancers and lymphomas |
| CN108424454B (zh) | 2007-08-14 | 2022-05-31 | 路德维格癌症研究所有限公司 | 靶向egf受体的单克隆抗体175及其衍生物和用途 |
| DK3281952T3 (da) | 2007-10-30 | 2020-08-03 | Philogen Spa | Antigen, der er forbundet med reumatoid artritis |
| JP6014706B2 (ja) * | 2008-02-14 | 2016-10-25 | 株式会社イーベック | ｈＧＭ−ＣＳＦに結合するモノクローナル抗体および前記抗体を含む医薬組成物 |
| WO2009127249A1 (en) * | 2008-04-16 | 2009-10-22 | United Technologies Ut Ag | Method for identifying compounds suitable for stimulation of stem cell production in skin |
| US20100009390A1 (en) * | 2008-05-09 | 2010-01-14 | The Regents Of The University Of California | Mutant antibodies with high affinity for egfr |
| US20100008978A1 (en) * | 2008-05-09 | 2010-01-14 | The Regents Of The University Of California | Nanoparticles effective for internalization into cells |
| AU2009270988A1 (en) | 2008-07-15 | 2010-01-21 | Genentech, Inc. | Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds |
| CA2748401C (en) | 2009-01-07 | 2017-09-12 | Philogen S.P.A. | Antigens associated with endometriosis |
| ES3000111T3 (en) | 2009-02-13 | 2025-02-27 | Immunomedics Inc | Intermediates for preparing conjugates with an intracellularly-cleavable linkage |
| US20160095939A1 (en) | 2014-10-07 | 2016-04-07 | Immunomedics, Inc. | Neoadjuvant use of antibody-drug conjugates |
| NZ713967A (en) | 2009-07-28 | 2017-01-27 | Shire Human Genetic Therapies | Compositions and methods for treating gaucher disease |
| EP2461832B1 (de) | 2009-08-05 | 2017-06-28 | Philogen S.p.A. | Abzielung auf die neovaskulatur des knochenmarks |
| US8524239B2 (en) | 2010-07-09 | 2013-09-03 | The United States of America as represented by the Secrectary, Department of Health and Human Services | Photosensitizing antibody-fluorophore conjugates |
| CN102258789B (zh) * | 2010-12-29 | 2013-04-24 | 海南医学院 | 小型化Endoglin抗体与阿霉素的偶联物及其制备方法 |
| CA2841120C (en) * | 2011-07-11 | 2020-10-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibody-ir700 conjugates for photodynamic therapy |
| EP2589609A1 (de) * | 2011-11-03 | 2013-05-08 | Pierre Fabre Medicament | Antigenbindendes Protein und dessen Verwendung als Adressierungsprodukt bei der Behandlung von Krebs |
| CN104519905A (zh) | 2012-03-02 | 2015-04-15 | 夏尔人类遗传性治疗公司 | 用于治疗iii型戈谢病的组合物和方法 |
| EP2859017B1 (de) | 2012-06-08 | 2019-02-20 | Sutro Biopharma, Inc. | Antikörper mit nichtnatürlichen stellenspezifischen aminosäureresten, verfahren zu deren herstellung und verfahren zu deren verwendung |
| WO2014004639A1 (en) | 2012-06-26 | 2014-01-03 | Sutro Biopharma, Inc. | Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use |
| CN104379169A (zh) | 2012-08-14 | 2015-02-25 | Ibc药品公司 | 用于治疗疾病的t-细胞重定向双特异性抗体 |
| ES2743423T3 (es) | 2012-10-03 | 2020-02-19 | Philogen Spa | Conjugado de anticuerpos para su uso en el tratamiento de una enfermedad inflamatoria intestinal |
| ES2773710T3 (es) | 2012-10-11 | 2020-07-14 | Daiichi Sankyo Co Ltd | Enlazadores para conjugados de anticuerpo - fármaco |
| WO2014061277A1 (ja) | 2012-10-19 | 2014-04-24 | 第一三共株式会社 | 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート |
| WO2017004144A1 (en) | 2015-07-01 | 2017-01-05 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
| CN107753954A (zh) | 2012-12-13 | 2018-03-06 | 免疫医疗公司 | 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量 |
| JP2016513098A (ja) | 2013-02-07 | 2016-05-12 | イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． | 癌の標的治療用抗体と抱合した極めて強力なプロドラック形態の２−ピロリノドキソルビシン（ｐ２ｐｄｏｘ） |
| US10071170B2 (en) * | 2013-06-24 | 2018-09-11 | Ablbio | Antibody-drug conjugate having improved stability and use thereof |
| WO2015006555A2 (en) | 2013-07-10 | 2015-01-15 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| WO2015047510A1 (en) * | 2013-09-27 | 2015-04-02 | Immunomedics, Inc. | Anti-trop-2 antibody-drug conjugates and uses thereof |
| AU2014371934B2 (en) * | 2013-12-25 | 2020-01-23 | Daiichi Sankyo Company, Limited | Anti-TROP2 antibody-drug conjugate |
| IL310627B2 (en) | 2014-01-31 | 2026-04-01 | Daiichi Sankyo Co Ltd | Anti-HER2 antibody-drug conjugates, compositions containing them and uses thereof |
| JP6447933B2 (ja) | 2014-02-21 | 2019-01-09 | アイビーシー ファーマスーティカルズ，インコーポレイテッド | Ｔｒｏｐ−２発現細胞に対する免疫応答を誘発することによる疾患治療 |
| EP3130608B1 (de) | 2014-04-10 | 2019-09-04 | Daiichi Sankyo Co., Ltd. | (anti-her2-antikörper)-arzneimittelkonjugat |
| KR102445502B1 (ko) | 2014-04-10 | 2022-09-21 | 다이이찌 산쿄 가부시키가이샤 | 항her3 항체-약물 콘주게이트 |
| EP3160504B1 (de) | 2014-06-24 | 2020-09-16 | Immunomedics, Inc. | Antihistontherapie für vaskuläre nekrose bei schwerer glomerulonephritis |
| US10830678B2 (en) | 2014-08-08 | 2020-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Photo-controlled removal of targets in vitro and in vivo |
| WO2016040825A1 (en) * | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anthracycline disulfide intermediates, antibody-drug conjugates and methods |
| EP3200822B1 (de) | 2014-09-30 | 2021-04-14 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Bindungsmoleküle, insbesondere antikörper die sich an l1cam (cd171) binden |
| US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| EP3865139B1 (de) | 2015-02-18 | 2023-05-03 | Enlivex Therapeutics Rdo Ltd | Kombinationsimmuntherapie und cytokinkontrolltherapie zur krebsbehandlung |
| WO2016170541A1 (en) | 2015-04-21 | 2016-10-27 | Enlivex Therapeutics Ltd. | Therapeutic pooled blood apoptotic cell preparations and uses thereof |
| AU2016252771B2 (en) | 2015-04-22 | 2021-12-16 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells |
| JP6980980B2 (ja) | 2015-06-25 | 2021-12-15 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | 抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する |
| CN116059395A (zh) * | 2015-06-29 | 2023-05-05 | 第一三共株式会社 | 用于选择性制造抗体-药物缀合物的方法 |
| CN121270700A (zh) | 2015-08-07 | 2026-01-06 | 美国政府(由卫生和人类服务部的部长所代表) | 用于治疗癌症的针对抑制细胞的近红外光免疫疗法(nir-pit) |
| ES2889904T3 (es) | 2015-08-18 | 2022-01-14 | Rakuten Medical Inc | Conjugados de colorante de ftalocianina y su almacenamiento |
| US11154620B2 (en) | 2015-08-18 | 2021-10-26 | Rakuten Medical, Inc. | Compositions, combinations and related methods for photoimmunotherapy |
| CN105288639A (zh) * | 2015-11-23 | 2016-02-03 | 中国药科大学 | 一种载阿霉素的主动靶向白蛋白纳米载体的制备及其应用 |
| US11583593B2 (en) | 2016-01-14 | 2023-02-21 | Synthis Therapeutics, Inc. | Antibody-ALK5 inhibitor conjugates and their uses |
| WO2017132615A1 (en) | 2016-01-27 | 2017-08-03 | Sutro Biopharma, Inc. | Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates |
| CN109069539A (zh) | 2016-02-18 | 2018-12-21 | 恩立夫克治疗有限责任公司 | 用于癌症治疗的联合免疫疗法和细胞因子控制疗法 |
| WO2017207540A1 (en) | 2016-05-30 | 2017-12-07 | Toxinvent Oü | Antibody-drug-conjugates comprising novel anthracycline-derivatives for cancer treatment |
| US11273155B2 (en) | 2016-12-12 | 2022-03-15 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and immune checkpoint inhibitor |
| AU2017383142A1 (en) | 2016-12-22 | 2019-07-04 | Università Degli Studi Magna Graecia Catanzaro | A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of CD43 |
| TW202532104A (zh) | 2017-05-15 | 2025-08-16 | 日商第一三共股份有限公司 | 抗體－藥物結合物及其用途 |
| IL324591A (en) | 2017-08-31 | 2026-01-01 | Daiichi Sankyo Co Ltd | Improved antibody-drug conjugate production methods |
| CA3074208C (en) | 2017-08-31 | 2023-10-03 | Daiichi Sankyo Company, Limited | Novel method for producing antibody-drug conjugate |
| SG11202010496WA (en) | 2018-05-18 | 2020-12-30 | Daiichi Sankyo Co Ltd | Anti-muc1 antibody-drug conjugate |
| WO2020013803A1 (en) * | 2018-07-09 | 2020-01-16 | Synthis, Llc | Antibody-alk5 inhibitor conjugates and their uses |
| WO2020022475A1 (ja) | 2018-07-27 | 2020-01-30 | 第一三共株式会社 | 抗体－薬物コンジュゲートの薬物部位を認識する蛋白質 |
| CA3108044A1 (en) | 2018-07-31 | 2020-02-06 | Daiichi Sankyo Company, Limited | Treatment of metastatic brain tumor by administration of antibody-drug conjugate |
| CN109761427B (zh) * | 2019-03-04 | 2021-07-20 | 南京信息工程大学 | 一种生产石墨烯工厂产生的污水的资源化方法 |
| WO2022010797A2 (en) | 2020-07-07 | 2022-01-13 | Bionecure Therapeutics, Inc. | Novel maytansinoids as adc payloads and their use for the treatment of cancer |
| WO2022239720A1 (ja) | 2021-05-10 | 2022-11-17 | 公益財団法人川崎市産業振興財団 | 抗原への結合親和性を低減させた抗体 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5066789A (en) * | 1988-09-30 | 1991-11-19 | Neorx Corporation | Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages |
| CA2048089A1 (en) * | 1990-09-17 | 1992-03-18 | Wolfgang A. Wrasidlo | Chemical conjugation of morpholino anthracyclines to antibodies |
| US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| AU1140495A (en) * | 1994-01-27 | 1995-08-03 | Bristol-Myers Squibb Company | Method for preparing thioether conjugates |
| US5843903A (en) * | 1995-11-27 | 1998-12-01 | The Administrators Of The Tulane Educational Fund | Targeted cytotoxic anthracycline analogs |
| DK0871490T3 (da) * | 1995-12-22 | 2003-07-07 | Bristol Myers Squibb Co | Forgrenede hydrazonlinkere |
| US7312318B2 (en) * | 2002-03-01 | 2007-12-25 | Immunomedics, Inc. | Internalizing anti-CD74 antibodies and methods of use |
| DE60042785D1 (de) * | 1999-06-09 | 2009-10-01 | Immunomedics Inc | Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern |
| US20040136908A1 (en) * | 2001-04-09 | 2004-07-15 | Olson William C. | Anti-cd19 immunotoxins |
| KR100863624B1 (ko) * | 2001-05-11 | 2008-10-15 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | Ｃｄ26을 발현하는 세포와 연관된 질환의 치료제로사용되는 항-ｃｄ26 단클론항체 |
| WO2003068821A2 (en) * | 2002-02-14 | 2003-08-21 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
| CA2478047C (en) * | 2002-03-01 | 2014-01-21 | Immunomedics, Inc. | Rs7 antibodies |
-
2004
- 2004-01-15 US US10/757,543 patent/US20040202666A1/en not_active Abandoned
- 2004-01-20 WO PCT/US2004/001367 patent/WO2004067038A1/en not_active Ceased
- 2004-01-20 MX MXPA05007851A patent/MXPA05007851A/es active IP Right Grant
- 2004-01-20 JP JP2006502890A patent/JP4805137B2/ja not_active Expired - Fee Related
- 2004-01-20 CA CA2510664A patent/CA2510664C/en not_active Expired - Fee Related
- 2004-01-20 AT AT04703628T patent/ATE500845T1/de not_active IP Right Cessation
- 2004-01-20 RU RU2005126717/15A patent/RU2349343C2/ru not_active IP Right Cessation
- 2004-01-20 BR BR0406574-3A patent/BRPI0406574A/pt not_active Application Discontinuation
- 2004-01-20 EP EP04703628A patent/EP1594548B1/de not_active Expired - Lifetime
- 2004-01-20 DE DE602004031714T patent/DE602004031714D1/de not_active Expired - Lifetime
- 2004-01-20 PL PL378012A patent/PL378012A1/pl unknown
- 2004-01-20 AU AU2004207494A patent/AU2004207494C1/en not_active Ceased
- 2004-01-20 KR KR1020057013686A patent/KR101053739B1/ko not_active Expired - Fee Related
- 2004-01-20 CN CN200480007880.XA patent/CN1764478B/zh not_active Expired - Fee Related
-
2005
- 2005-05-26 US US11/137,385 patent/US20050271671A1/en not_active Abandoned
- 2005-07-19 IL IL169769A patent/IL169769A/en active IP Right Grant
-
2009
- 2009-08-26 AU AU2009212806A patent/AU2009212806B2/en not_active Ceased
-
2010
- 2010-10-18 JP JP2010233918A patent/JP5501927B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2510664A1 (en) | 2004-08-12 |
| CA2510664C (en) | 2012-04-17 |
| CN1764478B (zh) | 2015-10-21 |
| BRPI0406574A (pt) | 2006-01-17 |
| MXPA05007851A (es) | 2005-10-18 |
| PL378012A1 (pl) | 2006-02-20 |
| DE602004031714D1 (de) | 2011-04-21 |
| RU2349343C2 (ru) | 2009-03-20 |
| AU2004207494C1 (en) | 2009-11-05 |
| EP1594548A1 (de) | 2005-11-16 |
| RU2005126717A (ru) | 2006-02-10 |
| CN1764478A (zh) | 2006-04-26 |
| KR20050104354A (ko) | 2005-11-02 |
| JP5501927B2 (ja) | 2014-05-28 |
| JP2006515892A (ja) | 2006-06-08 |
| WO2004067038A1 (en) | 2004-08-12 |
| JP2011012083A (ja) | 2011-01-20 |
| IL169769A (en) | 2011-11-30 |
| EP1594548B1 (de) | 2011-03-09 |
| KR101053739B1 (ko) | 2011-08-02 |
| US20050271671A1 (en) | 2005-12-08 |
| JP4805137B2 (ja) | 2011-11-02 |
| AU2009212806B2 (en) | 2011-12-08 |
| US20040202666A1 (en) | 2004-10-14 |
| AU2009212806A1 (en) | 2009-09-17 |
| AU2004207494B2 (en) | 2009-05-28 |
| AU2004207494A1 (en) | 2004-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE500845T1 (de) | Anthracyclin-anti-cd74-antikörperkonjugate | |
| WO2005032454A3 (en) | Anti-muc-1 single chain antibodies for tumor targeting | |
| CY1119291T1 (el) | Πολυσθενη αντισωματα και χρησεις για αυτα | |
| NO20083891L (no) | Anti-5T4 antistoffer og anvendelser derav | |
| NO20072670L (no) | PLAD domene peptider med okt halveringstid i serum pa grunn av konjugering til domene antistoffer | |
| EP2684889A3 (de) | Mit einem zielgerichteten menschlichen monoklonalen Antikörper komplexierte multivariable Antigene | |
| NO20071436L (no) | Humaniserte Anti-5T4 antistoffer og Anti-5T4 antistoff/calicheamicin konjugater | |
| WO2004010957A3 (en) | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease | |
| IL176940A (en) | An isolated antibody or antigen-binding fragment thereof | |
| WO2007112193A3 (en) | Camptothecin-binding moiety conjugates | |
| EA200600275A1 (ru) | Цитотоксический конъюгат, специфичный по отношению к са6 антигену, и способы его применения | |
| CY1118053T1 (el) | Φαρμακευτικες συνθεσεις με ανθεκτικοτητα σε διαλυτο cea | |
| EP1871417A4 (de) | Rekombinante monoklonale antikörper und entsprechende antigene für kolon- und pankreaskarzinom | |
| WO2005118642A3 (en) | Bispecific fusion antibodies with enhanced serum half-life | |
| CY1116632T1 (el) | Εξουδετερωτες αντισωματων του τελεστη διεγερσης αποικιων κοκκιοκυτταρων μακροφαγων ανθρωπου | |
| AU9399501A (en) | Therapeutic antibodies | |
| EA011859B9 (ru) | Соединения для адресной доставки препарата к ткани или органу-мишени | |
| CY2014002I2 (el) | Προϊοντα συζευξης μεϋτανσινοειδους dm1 με αντισωμα trastuzumab, συνδεδεμενα μεσω μη-διασπασιμου συνδετηρα και χρηση αυτων στη θεραπεια ογκων | |
| ATE455127T1 (de) | Humane anti-humane cd3-bindungsmoleküle | |
| EP2570137A3 (de) | Antikörper zur Bindung von humaner dendritischer und Epithelzelle 205 (DEC-205) | |
| BRPI0411854A (pt) | veìculos protéicos para vacinas | |
| GB2383331A (en) | Monoclonal antibody DS6 Tumor-associated antigen CA6 and methods of use thereof | |
| CR20210324A (es) | Anticuerpos anti-pmel 17 y conjugados de los mismos | |
| GB0008305D0 (en) | Treatment of fungal infections | |
| DE60315827D1 (de) | Verbesserte polysaccharid- und glykokonjugat-vakzine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |